

VORICONAZOLE SERUM CONCENTRATIONS MONITORING

C. MOYA MANGAS¹, L. AMARO¹, M.J. TIRADO¹, V. MERINO¹

1. HOSPITAL UNIVERSITARIO VIRGEN MACARENA, HOSPITAL PHARMACY, SEVILLA, SPAIN

Background and importance

Managing infections with voriconazole is a challenge due to its narrow therapeutic range and significant interindividual variability.

Aim and objectives

To describe serum levels of voriconazole in a cohort of patients in two tertiary-level hospitals.

Material and methods



Descriptive observational retrospective multicenter study.



1st Jan - 31st Aug 2023.



6mg/kg (1st day).

4mg/kg/12h (maintenance).



HPLC

Results

53 patients, 90 determinations.



67.9%.



62.7 ± 9.8 years.



68.6 ± 17.3 kg.

LEVELS


THERAPEUTIC* → same dose

SUBTHERAPEUTIC (0,7 ± 2.7) → ↑ dose 25-50%/ isavuconazole

SUPRATHERAPEUTIC (7.2 ± 2.7) → ↓ dose 25-50%


*Therapeutic range: 1.5-5.5 mg/L.

Range



■ Therapeutic range
■ No therapeutic range

Levels



■ Subtherapeutic
■ Supratherapeutic

Conclusion and relevance

Monitoring voriconazole serum levels is a necessity to adjust the dose to reach effective levels and avoid toxicity.



Contact data



Celia Moya Mangas

celia.moya.sspa@juntadeandalucia.es

Hospital Universitario Virgen Macarena.
Av. Dr. Fedriani, 3. Sevilla, 41009.